Michael Walsh1, Mikkel Faurschou2, Annelies Berden3, Oliver Flossmann4, Ingeborg Bajema3, Peter Hoglund5, Rona Smith6, Wladimir Szpirt7, Kerstin Westman8, Charles D Pusey9, David R W Jayne6. 1. Departments of Medicine and Clinical Epidemiology and Biostatistics, Population Health Research Institute, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada; lastwalsh1975@gmail.com. 2. Departments of Infectious Diseases and Rheumatology and. 3. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 4. Renal Unit, Royal Berkshire Hospital, Reading, United Kingdom; 5. Competence Centre for Clinical Research, University Hospital Lund, Lund, Sweden; 6. Renal Unit, Addenbrooke's Hospital, Cambridge, United Kingdom; 7. Nephrology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 8. Department of Nephrology and Transplantation, Skane University Hospital, Malmö, Sweden; and. 9. Department of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Abstract
BACKGROUND AND OBJECTIVES: Treatment with azathioprine within 3 months of remission induction with cyclophosphamide is a common treatment strategy for patients with ANCA-associated vasculitis. This study comprised patients undergoing long-term follow-up who were randomly allocated to azathioprine after 3-6 months or after 12 months of cyclophosphamide treatment. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients from 39 European centers between 1995 and 1997 with a new diagnosis of ANCA-associated vasculitis that involved the kidneys or another vital organ were eligible. At the time of diagnosis, participants were randomly allocated to convert to azathioprine after 3-6 months (the azathioprine group) or after 12 months of cyclophosphamide (the cyclophosphamide group). Patients who did not achieve a remission within 6 months were excluded. This study assessed relapses, ESRD, and death during long-term follow-up. RESULTS: Patients were allocated to the azathioprine group (n=71) and the cyclophosphamide group (n=73). Of these patients, 63 (43.8%) developed a relapse, 35 (24.3%) developed a renal relapse, 13 (9.0%) developed ESRD, and 21 (14.6%) died. Although there were worse outcomes in the azathioprine group, none were statistically significant. The subdistribution hazard ratio [sHR] for relapse was 1.63 (95% confidence interval [95% CI], 0.99 to 2.71), the composite of relapse or death hazard ratio [HR] was 1.59 (95% CI, 1.00 to 2.54), the ESRD sHR was 1.71 (95% CI, 0.56 to 5.19), and the death HR was 0.75 (95% CI, 0.32 to 1.79). CONCLUSIONS: It remains uncertain whether converting to azathioprine after 3-6 months of induction cyclophosphamide therapy is as effective as converting after 12 months. Outcomes are still poor for this group of patients and further research is required to determine the optimal timing of maintenance therapy.
RCT Entities:
BACKGROUND AND OBJECTIVES: Treatment with azathioprine within 3 months of remission induction with cyclophosphamide is a common treatment strategy for patients with ANCA-associated vasculitis. This study comprised patients undergoing long-term follow-up who were randomly allocated to azathioprine after 3-6 months or after 12 months of cyclophosphamide treatment. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients from 39 European centers between 1995 and 1997 with a new diagnosis of ANCA-associated vasculitis that involved the kidneys or another vital organ were eligible. At the time of diagnosis, participants were randomly allocated to convert to azathioprine after 3-6 months (the azathioprine group) or after 12 months of cyclophosphamide (the cyclophosphamide group). Patients who did not achieve a remission within 6 months were excluded. This study assessed relapses, ESRD, and death during long-term follow-up. RESULTS:Patients were allocated to the azathioprine group (n=71) and the cyclophosphamide group (n=73). Of these patients, 63 (43.8%) developed a relapse, 35 (24.3%) developed a renal relapse, 13 (9.0%) developed ESRD, and 21 (14.6%) died. Although there were worse outcomes in the azathioprine group, none were statistically significant. The subdistribution hazard ratio [sHR] for relapse was 1.63 (95% confidence interval [95% CI], 0.99 to 2.71), the composite of relapse or death hazard ratio [HR] was 1.59 (95% CI, 1.00 to 2.54), the ESRD sHR was 1.71 (95% CI, 0.56 to 5.19), and the death HR was 0.75 (95% CI, 0.32 to 1.79). CONCLUSIONS: It remains uncertain whether converting to azathioprine after 3-6 months of induction cyclophosphamide therapy is as effective as converting after 12 months. Outcomes are still poor for this group of patients and further research is required to determine the optimal timing of maintenance therapy.
Authors: John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani Journal: Ann Rheum Dis Date: 2008-04-15 Impact factor: 19.103
Authors: C Lapraik; R Watts; P Bacon; D Carruthers; K Chakravarty; D D'Cruz; L Guillevin; L Harper; D Jayne; R Luqmani; J Mooney; D Scott Journal: Rheumatology (Oxford) Date: 2007-09-05 Impact factor: 7.580
Authors: Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne Journal: Ann Rheum Dis Date: 2011-11-29 Impact factor: 19.103
Authors: David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: C Talar-Williams; Y M Hijazi; M M Walther; W M Linehan; C W Hallahan; I Lubensky; G S Kerr; G S Hoffman; A S Fauci; M C Sneller Journal: Ann Intern Med Date: 1996-03-01 Impact factor: 25.391
Authors: H Marco; J Draibe; J Villacorta; L F Quintana; N Martin; R Garcia-Osuna; C Cabre; M A Martín-Gómez; A Balius; A Saurina; M Picazo; I Gich-Saladich; M Navarro-Díaz; M Praga; T Cavero; J Ballarin; M M Díaz-Encarnación Journal: Clin Rheumatol Date: 2018-03-09 Impact factor: 2.980
Authors: Michael Walsh; Peter A Merkel; Chen-Au Peh; Wladimir M Szpirt; Xavier Puéchal; Shouichi Fujimoto; Carmel M Hawley; Nader Khalidi; Oliver Floßmann; Ron Wald; Louis P Girard; Adeera Levin; Gina Gregorini; Lorraine Harper; William F Clark; Christian Pagnoux; Ulrich Specks; Lucy Smyth; Vladimir Tesar; Toshiko Ito-Ihara; Janak Rashme de Zoysa; Wojciech Szczeklik; Luis Felipe Flores-Suárez; Simon Carette; Loïc Guillevin; Charles D Pusey; Alina L Casian; Biljana Brezina; Andrea Mazzetti; Carol A McAlear; Elizabeth Broadhurst; Donna Reidlinger; Samir Mehta; Natalie Ives; David R W Jayne Journal: N Engl J Med Date: 2020-02-13 Impact factor: 91.245
Authors: Uta Erdbrügger; Jan T Kielstein; Kerstin Westman; Jennie Z Ma; Wenjun Xin; Stephanie M Bode-Böger; Mȧrten Segelmark; Niels Rasmussen; Kirsten De Groot Journal: Eur J Rheumatol Date: 2018-04-02
Authors: Ruth J Pepper; Juliana B Draibe; Ben Caplin; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks; Peter A Merkel; Alan D Salama Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 10.995
Authors: Rennie L Rhee; Susan L Hogan; Caroline J Poulton; Julie Anne G McGregor; J Richard Landis; Ronald J Falk; Peter A Merkel Journal: Arthritis Rheumatol Date: 2016-07 Impact factor: 10.995